Drug intelligence / Profile preview

BLB-102

Development stage: Preclinical
Lead developer: BayLink Biosciences
Modality: Small Molecules
Administration: Oral

Overview

BLB-102 is a Topoisomerase 1 (TOP1) inhibitor being developed by BayLink Biosciences for the treatment of triple-negative breast cancer (TNBC). The drug functions by inhibiting the DNA topoisomerase 1 enzyme, which is essential for relieving torsional strain during DNA replication and transcription. By stabilizing the TOP1-DNA covalent complex, BLB-102 induces DNA strand breaks, leading to cell cycle arrest and apoptosis in malignant cells. The program is currently in the IND-enabling stage of development.

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on BLB-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BLB-102.

Explore the full profile